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Mesenchymal stem cells from pediatric patients (pMSCs) are an attractive cell source in
regenerative medicine, due to their higher proliferation rates and better differentiation
abilities compared to adult MSCs (aMSCs). We have previously characterized the
immunomodulatory abilities of pMSCs on T cells under co-culture. It has also been
reported that aMSCs can inhibit B cell proliferation and maturation under inflammatory
conditions. In this study, we therefore aimed to clarify the immunomodulatory effect
of pMSCs toward T and B cells in an inflammatory microenvironment. Bone marrow
derived pMSCs were primed to simulate inflammatory conditions by exposure with
50 ng/mL of IFN-γ for 3 days. To analyze the interaction between pMSCs and T cells,
CD3/CD28 stimulated peripheral blood mononuclear cells (PBMCs) were co-cultured
with primed or unprimed pMSCs. To investigate B cell responses, quiescent B cells
obtained from spleens by CD43 negative selection were stimulated with anti-IgM,
anti-CD40, IL-2, and co-cultured with either IFN-γ primed or unprimed pMSC. pMSC
phenotype, B and T cell proliferation, and B cell functionality were analyzed. Gene
expression of indoleamine 2,3-dioxygenease (IDO), as well as the expression of
HLA-ABC, HLA-DR and the co-stimulatory molecules CD80 and CD86 was upregulated
on pMSCs upon IFN-γ priming. IFN-γ did not alter the immunomodulatory abilities
of pMSCs upon CD4+ nor CD8+ stimulated T cells compared to unprimed pMSCs.
IFN-γ primed pMSCs but not unprimed pMSCs strongly inhibited naïve (CD19+CD27−),
memory (CD19+CD27+), and total B cell proliferation. Antibody-producing plasmablast
(CD19+CD27highCD38high) formation and IgG production were also significantly inhibited
by IFN-γ primed pMSCs compared to unprimed pMSCs. Collectively, these results show
that pMSCs have immunomodulatory effects upon the adaptive immune response which
can be potentiated by inflammatory stimuli. This knowledge is useful in regenerative
medicine and allogeneic transplantation applications toward tailoring pMSCs function to
best modulate the immune response for a successful implant engraftment and avoidance
of a strong immune reaction.
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INTRODUCTION
Mesenchymal stem cells (MSCs) are a source of self-renewing
multipotent stem cells that are capable of differentiating along
adipogenic, osteogenic, and chondrogenic lineages (Chamberlain
et al., 2007; Bianco et al., 2008). MSCs are also known to
exert potent immunomodulatory effects upon a wide range of
immune cells, both of the innate and the adaptive immune
system (Gao et al., 2016). This effect seems to be dependent
upon the inflammatory conditions of the micro-environment in
which these MSCs are found (Krampera et al., 2006; Cuerquis
et al., 2014). Particularly for the adaptive immune response, pro-
inflammatory cytokines, such as IFN-γ, seem to potentiate the
anti-proliferative effect of MSC on T cells by inducing an increase
in the activity of the enzyme indoleamine 2,3-dioxygenease
(IDO) (Meisel et al., 2004). Regarding their interaction with B
cells, MSCs have been described to suppress B cell proliferation
through soluble factors (Corcione et al., 2006) and abrogate
plasmablast formation independently of T cells (Franquesa et al.,
2015). It has also been shown that upon IFN-γ stimulation,
MSCs significantly inhibit B cell proliferation and maturation by
upregulating IDO expression (Luk et al., 2017).
Due to their multipotent differentiation and immune
modulation properties, MSCs have been successfully investigated
for their use in several diseases such as ischemia (Cortez-Toledo
et al., 2018), autoimmune diseases (Gerdoni et al., 2007; González
et al., 2009), as well as in solid organ transplantation (Benseler
et al., 2014). Other applications of MSCs include their potential
use in tissue engineering and regenerative medicine (Barry and
Murphy, 2013; Shao et al., 2015). In particular in this field,
bone marrow derived MSCs (BM-MSCs) have been successfully
differentiated toward a chondrogenic phenotype and used for
in vivo bone formation following the process of endochondral
ossification (Farrell et al., 2011; van der Stok et al., 2014).
Nevertheless, the high variability between BM-MSC donors as
a result of age and disease status has been shown to have
an increasing importance by negatively influencing their bone
formation potential in the case of elderly donors (Stolzing, 2006;
Ganguly et al., 2017). Hence, a source of BM-MSCs with less
age related variations are potentially more promising candidates
for these applications (Stolzing, 2006). Pediatric BM-MSCs
(pMSCs) obtained from iliac crest bone chips from individuals
between 7 and 13 years old have increased differentiation and
proliferation capacities compared to adult BM-MSCs (aMSCs)
(Knuth et al., 2018). pMSCs have been described to maintain an
immunophenotype identical to aMSCs and are significantly less
senescent (Knuth et al., 2018).
In the context of an allogeneic transplantation, the adaptive
immune response plays an important role in determining the
outcome of the engraftment of the allograft (Cozzi et al., 2017).
Naïve and memory CD4+ and CD8+ alloreactive T cells mediate
rejection and graft-vs.-host disease processes (Cozzi et al., 2017;
DeWolf and Sykes, 2017). The cross-talk between B and T cells is
critical in these immune responses, since B cells are known to be
the mediators of humoral rejection by producing donor-specific
human leukocyte antigen (HLA) antibodies upon activation by T
cells (Larsen et al., 2006).
We have previously shown that pMSCs can exert
an immunomodulatory effect on T cells by reducing
their proliferation rates in an in vitro co-culture model
(Knuth et al., 2018). Since in an allogeneic transplantation
setting pMSCs might be subjected to an inflammatory
microenvironment their immune properties might also be
altered, affecting their success for clinical uses. Hence, to
characterize how the inflammatory microenvironment can
affect their immune status, in this study we investigated
the effect of IFN-γ priming of a novel source of pMSCs
on their immunomodulatory functionality toward B and
T cells.
METHODS
Isolation and Culture of Human Pediatric
Bone Marrow Derived MSCs (pMSCs)
pMSCs were isolated from leftover iliac crest bone chips
of pediatric patients undergoing alveolar bone graft surgery.
Written consent was not required according to institutional
guidelines for the use of waste surgical material but an opt out
was available. This was approved by the Erasmus Medical Ethical
Committee (MEC-2014-16). The age of the patients ranged
between 9 and 13 years old Detailed information about age and
sex of the donors can be found in Table 1.
Briefly, pMSCs were obtained by washing the iliac crest chips
twice with 10mL of αMEM expansion medium supplemented
with 10% heat inactivated fetal bovine serum, 1.5µg/mL
Amphotericin B, 25µg/mL L-ascorbic acid 2-phosphate,
50µg/mL gentamycin (all from Invitrogen) and 1 ng/mL
fibroblast growth factor-2 (BioRad). The medium from the two
washes containing the pMSCs was then plated in T75 flasks
which were washed twice 24 h after with phosphate-buffered
saline (PBS) supplemented with 2% v/v heat inactivated fetal
bovine serum to remove non-adherent dead cells. Viable
pMSCs were at all times cultured at 37◦C and 5% carbon
dioxide (CO2) in a humidified atmosphere. Expansion medium
was replaced at least twice a week and the cells were firstly
passaged when several visible colonies were detected using 0.05%
trypsin-EDTA (Invitrogen). Upon the second passage, cells were
always trypsinized at 70–80% of confluency. The cells showed
an MSC characteristic morphology and were used between
passages three and five for all experiments. Their phenotypic
characteristics were previously extensively described by our
group (Knuth et al., 2018).
TABLE 1 | Details of age and sex of the pMSC donors used in the study.
Donor Age (years) Sex
Donor 1 12 Male
Donor 2 12 Female
Donor 3 10 Female
Donor 4 10 Male
Donor 5 Between 9 and 13 Male
Donor 6 9 Male
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Isolation of PBMCs From Peripheral Blood
Peripheral blood from healthy male donors was obtained
from Sanquin Bloedvoorziening (Rotterdam, the Netherlands).
Samples were centrifuged at 388 g for 7min to remove the top
layer of plasma and washed at a 1:2 dilution in wash medium
(RPMI-1640 supplemented with 1.5µg/mL Amphotericin B
and 50µg/mL gentamycin). The remaining cell suspension was
then transferred to Ficoll-Paque PLUS (density 1.077 g/mL; GE
Healthcare) containing tubes and centrifuged at 690 g for 20min
with the brake turned off. The plasma was removed and the layers
above the filter were then washed with wash medium up to a
total volume of 50mL. Samples were then washed three times in
wash medium as in the previous step, and then finally cells were
counted and resuspended in human serum conditioned medium
(PBMC medium) composed of RPMI-1640 medium with 1% v/v
GlutaMAX, 1.5µg/mL Amphotericin B, 50µg/mL gentamycin
and 10% v/v heat inactivated human serum (Sigma-Aldrich).
Cells were then resuspended in PBMC medium supplemented
with a 10% of dimethylsulphoxide in appropriate numbers for
optimal conservation and stored in liquid nitrogen until used for
the experiments.
IFN-γ Pre-stimulation of pMSCs
Based on previous optimization experiments, pMSCs were pre-
treated for 3 days using IFN-γ (50 ng/mL, Peprotech) prior to
co-cultures (Luk et al., 2017). Twenty four hours before the co-
culture day, cells were detached with 0.05% w/v trypsin-EDTA,
washed with PBS and seeded in a 96 well plate at a density of
0.2 × 106 cells per well in either 100 µL of Iscove’s Modified
Dulbecco’s Medium (IMDM, Lonza) supplemented with a 10%
v/v heat inactivated FBS (for B cell co-cultures), or in 100 µL of
PBMC medium (for PBMC co-cultures).
Quantitative Real-Time Reverse
Transcription Polymerase Chain
Reaction (qRT-PCR)
After 3 days of IFN-γ stimulation, 0.3 × 106 pMSCs were placed
in 300 µL of RLT buffer and snap frozen. RNA was isolated using
a RNeasy micro kit (QIAGEN), and complementary cDNA was
synthetized using a first strand cDNA kit (RevertAid cDNA kit,
Thermo Scientific). qRT-PCR was performed using a 2x TaqMan
Universal PCR master mix (Applied Biosystems), according
to manufacturer’s instructions and assay on demand primers
(Thermoscientific) for IDO (Hs 00158027.m1) and for GAPDH
(forward: 5′-ATGGGGAAGGTGAAGGTCG-3′, reverse: 5′-
TAAAAGCAGCCCTGGTGACC-3′, probe (FAM-TAMRA):
5′ CGCCCAATACGACCAAATCCGTTGAC-3′). TAQ DNA
polymerase (Hot Start) was activated for 10min at 95◦C, then
DNA was amplified following 40 cycles of 15 s at 95◦C, and 1min
at 60◦C. TAQman was analyzed on a CFX-96 thermal cycler
(BioRad). Results are expressed as relative copy number of PCR
products in respect to the housekeeper GAPDH.
pMSC Phenotyping by Flow Cytometry
pMSCs were immunophenotypically analyzed with and without
IFN-γ pre-stimulation by assessing the expression of surface
markers: HLA-ABC FITC, HLA-DR PerCP (clone G46.6), CD80
PE-Cy7 (clone L307.4), CD86 PE (clone 2331 FUN-1), all from
BD Biosciences, San Jose, CA, USA by Flow Cytometry (FACS
Jazz, BD Biosciences, San Jose, CA, USA). A total of N = 3
different pMSC donors in triplicates were analyzed.
T Cell Proliferation Analysis
Isolated PBMCs were thawed in 10mL of pre-warmed PBMC
medium and centrifuged at 248 g for 8min. Cells were counted
and in order to track proliferation, they were resuspended to a
concentration of 107 cells/mL, and 20 µL of carboxyfluorescein
succinimidyl ester (CFSE, 5µM) were added per 0.980 µL of cell
suspension for 7min at 37◦C. After that time, cell suspensions
were topped up to a 10mL volume of cold PBMC medium, and
centrifuged 10min at 690 g. T cell proliferation was stimulated
using antibodies against CD3 and CD28 (1 mg/mL, 1 µL each
per 106 cells, BD Biosciences) and a Goat linker antibody (0.5
mg/mL, 2 µL per 106 cells, BD Biosciences). Stimulated PBMCs
were then added at 1:2.5, 1:5, 1:10 and 1:20 ratios to previously
seeded pMSCs and co-cultured for 5 days.
PBMCs were removed by careful aspiration from the wells
and washed with FACSflow. Cells were resuspended in 100 µL
of FACSflow containing antibodies and fixed overnight in 4.6%
paraformaldehyde. Prior to the analysis, samples were washed
and resuspended in 100 µL of FACSflow. To identify T cells
and specific subsets, antibodies against CD3 PerCP (clone SK7),
CD4 APC (SK3) and CD8 PE-Cy7 (SK1) were used (all from BD
Biosciences, San Jose, CA, USA). T cell proliferation was tracked
by flow cytometry using FACS Jazz. Samples were analyzed using
the software FlowJo V10.07 (BD Biosciences). N = 3 different
pMSC donors with N = 3 different PBMC donors in triplicates
were analyzed.
Isolation of B Cells From Spleens
Human splenocytes were obtained from the spleens of deceased
kidney donors [The Netherlands Law of organ donation
(Wet op Orgaandonatie, WOD), article 13]. Ficoll-Paque
(Amersham Pharmacia Biotech, Uppsala, Sweden) density
gradient separation was performed on spleens segments that were
previously mechanically disrupted and filtered with a 70µM cell
strainer. Mononuclear cells were stored at−150◦C until the date
of use. On the co-culture day, quiescent B cells were isolated
from thawn splenocytes by using anti-CD43 magnetic beads
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). CD19+
purity was determined on the CD43− fraction by flow cytometry
(FACS Canto II, BD Biosciences, San Jose, CA, USA) and cells
suspensions with a >97% purity were used.
B Cell Proliferation and Subset Analysis
Purified CD43− quiescent B cells were labeled with CFSE
(Molecular Probes Invitrogen, Karlsruhe, Germany) as described
previously for PBMC proliferation for 7min at 37◦C. After
labeling, B cells were resuspended in IMDM with 10% v/v
heat inactivated FBS supplemented with a cocktail to mimic
T cell activation, composed of 1,000 UI/mL IL-2 (Proleukin,
Novartis, Prometheus laboratories Inc., San Diego, CA, USA),
10µg/mL Goat anti-human IgM (Jackson Immunoresearch,
Cambridgeshire, UK), and 5µg/mL soluble recombinant human
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CD40L (Biolegend, San Diego, CA, USA). One hundred
microliter per well of the previously described cell suspension
were added to the previously seeded pMSCs at a 1:5 MSC:B cell
ratio and co-cultured for 7 days.
B cell proliferation was characterized by flow cytometry (FACS
Canto II) and analyzed with FlowJo V10.07 (BD Biosciences).
Samples were collected by careful aspiration and centrifuged
for 5min at 690 g, and supernatants were stored at −80◦C
for IgG quantification. Cells were stained using the following
flow cytometry antibodies: CD19-BV512 (clone HIB19), CD27
PE-Cy7 (clone 0323), CD38-PE (clone HB7), Viaprobe (BD
Biosciences, San Jose, CA, USA). A total of N = 3 different B
cell donors co-cultured with one pMSC donor in duplicates or
triplicates were analyzed.
IgG ELISA
Human IgG present in the supernatants was quantified by using
a Human total IgG Ready SET Go ELISA kit (Thermofisher)
following the manufacturer’s instructions. Briefly, ELISA plates
were coated overnight in coating buffer. The next day, samples
were thawed in ice and diluted 1:2 in Assay buffer. Plates were
washed twice with 400 µL per well of Wash Buffer, and blocked
with 250 µL of Blocking buffer. One hundred microliter of
either 1:2 diluted samples or standard IgG were added to the
wells and incubated at room temperature for 2 hours with
400 rpm agitation. Upon incubation, wells were washed four
times and 100 µL of detection antibody was added for 1 h
at 400 rpm. After 4 washes, 100 µL per well of substrate
solution were added and incubated for 15min, upon when the
reaction was stopped by pipetting 100 µL of stop solution to
each well. Absorbance was read at 450 nm using a Versamax
plate reader.
Statistical Analysis
Data is expressed as mean ± Standard Deviation (SD), n =
3 (experimental replicates) in duplicates or triplicates unless
otherwise stated, where p < 0.05 values were considered
as statistically significant. For all B and T cell proliferation
analysis, N = 3 PBMC/B cell donors and a minimum of
N = 1 pMSC donors were used. Statistical analysis was
performed by the software IBM SPSS Version 24 using
a linear mixed model with Bonferroni post-correction
test for all figures, except for Figure 1A for which a
Mann-Whitney test was used. P-values are represented
as ∗∗∗p < 0.001, ∗∗p < 0.01, ∗p < 0.05.
RESULTS
IFN-γ Pre-treatment Upregulates the
Expression of IDO and Immune Related
Markers on pMSCs
To study the effect of IFN-γ on the expression of
immunomodulatory and co-stimulatory molecules on pMSCs,
50 ng/mL of IFN-γ was added to undifferentiated pMSCs for
3 days. After that time, the expression of IDO was quantified
by qRT-PCR, and CD80, CD86, HLA-ABC, and HLA-DR
surface levels were measured by FACS (Figure 1). Stimulation of
pMSCs with IFN-γ significantly upregulated the gene expression
levels of IDO (Figure 1A). Unprimed pMSC of all donors
were highly positive for HLA-ABC, whereas for the rest of
markers (CD80, CD86, and HLA-DR levels) unprimed cells
expressed <50% of positive cells. Upon IFN-γ stimulation
the percentage of positive cells of CD80, CD86, and HLA-DR
was increased for all donors. We also found an increase in the
expression levels per cell, expressed as the Mean Fluorescence
Intensity (MFI) of HLA-ABC and HLA-DR for all donors
(Figures 1B,C).
These results imply that IFN-γ pre-conditioning increases the
expression of the immunomodulatory related enzyme IDO, but
also the levels of HLA and co-stimulatory molecules involved in
the activation of B and T cells on pMSCs.
IFN-γ Pre-treatment on pMSCs Does Not
Affect Their Immunomodulatory Properties
Upon T Cells
To assess the immunomodulatory abilities of pMSCs toward T
cells under inflammatory conditions, IFN-γ primed or unprimed
pMSCs were co-cultured with stimulated PBMCs (+CD3/CD28
antibodies) at 1:2.5, 1:5, 1:10, and 1:20 pMSC:PBMC for 5 days
(Figure 2). The proliferation of CD4+ and CD8+ T cells was
tracked using CFSE. The reduction in T cell proliferation for
both CD4+ (Figure 2B) and CD8+ (Figure 2C) T cell subsets
induced by pMSCs was dose dependent for IFN-γ primed
or unprimed pMSCs co-cultures. However, there was not a
significant difference between the IFN-γ primed or unprimed
conditions for any of the doses tested. Hence, we concluded
that pMSCs are able to exert their immunomodulatory abilities
toward T cells regardless of the addition of IFN-γ.
IFN-γ Primed pMSCs Significantly Reduce
the Proliferation Rates of B Cells
To examine whether inflammatory conditions could influence
the anti-proliferative capacities of pMSCs on B cells, we co-
cultured IFN-γ primed pMSCs with stimulated B cells for 7 days.
We hypothesized that IFN-γ primed pMSCs would have similar
immunomodulatory capacities on B cells compared to aMSCs
(Luk et al., 2017).
B cells were stimulated with anti-CD40, anti-IgM, and IL-2 to
mimic T cell activation in the absence of T cells. Viable B cells
(Viaprobe− CD19+) were analyzed by FACS and classified into
CD27+ (memory) and CD27− (naïve) B cells or plasmablasts
(CD27high CD38high) (Figure 3A).
Co-culture of unprimed pMSCs with B cells did not
reduce proliferation rates of total B cells, naïve or memory
B cells, but a tendency toward an increased proliferation
was observed compared to stimulated B cells on their own.
However, IFN-γ pre-conditioning of pMSCs decreased the
proliferation rates of naïve, memory and total B cells in
co-cultures compared to stimulated B cells. Moreover, IFN-
γ primed pMSCs significantly decreased the proliferation
rates of all B cell subsets when compared to unprimed
pMSCs (Figure 3B).
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FIGURE 1 | Effect of IFN-γ on the expression of immune regulatory and co-stimulatory markers on pMSCs upon IFN-γ stimulation. pMSCs treated with 50 ng/mL
IFN-γ for 3 days or unprimed (-IFN-γ) pMSCs were analyzed for IDO gene expression by qRT-PCR, and stained for HLA-ABC, HLA-DR, CD80, and CD86 expression
and analyzed by FACS. (A) Expression of gene encoding for IDO relative to GAPDH. N = 3 pMSCs donors, single replicates. (B) Representative flow cytometry
histograms of HLA-DR, HLA-ABC, CD80, and CD86 expression (blue line) on pMSCs based on the unstained control (dot line) with and without the addition of IFN-γ.
(C) Percentage of positive cells and Mean Fluorescence Intensity (MFI) for HLA-ABC, HLA-DR, CD80, and CD86 markers. N = 3 different pMSC donors in triplicates.
Results are shown as means ± SD. *p < 0.05.
IFN-γ Primed pMSCs Abrogate
Plasmablast Differentiation and
IgG Production
After 7 days of co-culture with IFN-γ primed or
unprimed pMSCs, we determined the frequencies of
CD19+CD27highCD38high plasmablast cells by FACS
(Figure 3A). In order to characterize B cell functionality,
we quantified the amount of antibody released by B cells by
measuring the IgG production in the supernatants of the
co-cultures by ELISA.
Unprimed pMSCs did not significantly reduce the number
of plasmablasts when co-cultured together with stimulated B
cells (Figure 4A). However, there was a statistically significant
reduction in the percentage of plasmablasts detected when co-
cultured with IFN-γ primed pMSCs (8.9% of plasmablasts vs.
1.8%, respectively). A significant reduction in the amount of IgG
present in the supernatants was also found when B cells were
co-cultured with IFN-γ primed pMSCs compared to unprimed
pMSCs, from 43 to 14 ng/mL (Figure 4B).
DISCUSSION
The immunomodulatory abilities of MSCs upon the adaptive
immune response have been previously investigated in a
number of studies (Bartholomew et al., 2002; Su et al.,
2013; Franquesa et al., 2015; Luk et al., 2017). Moreover,
MSCs immunomodulatory properties upon T and B cells
have been shown to be highly influenced by the local
inflammatory microenvironment (Krampera et al., 2006). These
studies have reported some promising alternatives to tailor the
immunosuppressive abilities of MSCs, by subjecting them to
certain pro-inflammatory cytokines such as IFN-γ (Tipnis et al.,
2010; Luk et al., 2017). However, they were performed using
MSCs derived from diverse sources of aMSC donors, which
can lead to high variability and unpredictable results due to
a large age and origin variation among donors (Bruna et al.,
2016), as well as reduced immunomodulatory abilities associated
to age (Wu et al., 2014). We have previously established
that the use of a potent source of pMSCs with enhanced
multilineage differentiation and expansion abilities, as well as
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FIGURE 2 | pMSCs are immunomodulatory toward T cells in a dose-dependent manner. CD3/CD28 stimulated PBMCs were co-cultured with IFN-γ primed (+IFN-γ)
or unprimed (-IFN-γ) pMSCs at 1:2.5, 1:5, 1:10, and 1:20 pMSCs:PBMCs ratios. Flow cytometric analysis was performed after 5 days of co-culture, and CD4+ and
CD8+ proliferating T cells were detected by CFSE. (A) Representative FACS plots and histograms showing the gating strategy for stimulated CD4+ and CD8+ T cells
alone or in co-culture with unprimed or IFN-γ primed pMSCs. (B) CD4+ and (C) CD8+ T cell proliferation in co-culture with unprimed or IFN-γ primed pMSCs.
Results are expressed as the relative proliferation measured as the 1/Mean Fluorescence Intensity (MFI) of CFSE normalized to the (+CD3/CD28) stimulated control.
N = 3 different pMSC donors with N = 3 different PBMC donors in triplicates. Results are represented as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001.
reduced senescence, could make them attractive candidates for
regenerative medicine (Knuth et al., 2018). Moreover, in the
same study pMSCs were shown to reduce T cell proliferation
in an allogeneic in vitro co-culture model. Here, we aimed to
further investigate the immunomodulatory abilities of pMSCs
toward T and B cells under inflammatory conditions as a
promising MSC source for regenerative medicine and allogeneic
transplantation with more consistent differentiation abilities and
increased expansion properties.
Inflammatory signals have been suggested to alter the
immunomodulatory functionality of MSCs toward B cells
(Krampera et al., 2006). Luk et al. (2017) previously showed
that IFN-γ primed adipose derived aMSCs inhibited naïve
(CD19+CD27−) and memory (CD19+CD27+) B cell
proliferation. In this study we clarified the immunomodulatory
abilities of pMSCs upon stimulated B cells. Our findings suggest
that IFN-γ priming is crucial for pMSCs in order to exert their
immunomodulatory functionality upon B cells. IFN-γ primed
pMSCs but not unprimed pMSCs showed a significant reduction
in B cell proliferation for all different B cell subsets.
Franquesa et al. (2015) previously reported that in the
presence of adipose-derived MSCs, antibody producing
plasmablast (CD19+CD27highCD38high) formation was
inhibited. Hence, we hypothesized that pMSCs would also
reduce plasmablast differentiation and that this effect would
be enhanced by IFN-γ pre-priming. Our results showed that
pMSCs reduced the numbers of plasmablasts only upon priming
them with IFN-γ. We also showed that antibody production was
significantly decreased when IFN-γ primed pMSCs were present
and not in the presence of unprimed pMSCs. Since plasmablasts
possess an antibody-producing functionality, these results
suggest that in the case of an inflammatory microenvironment
pMSCs significantly suppress humoral responses mediated
by B cells. Moreover, since IFN-γ can be produced by T
cells upon activation, these results suggest that the cross-talk
between B and T cells might be of importance as a potential
source of IFN-γ that can promote pMSC’s immunosuppressive
mechanisms upon B cells. In the situation of an allogeneic
transplant, these properties of pMSCs might be advantageous to
avoid allo-antibody formation against the allograft, one of the
principal consequences of rejection and graft vs. host disease
(GvHD) (Young et al., 2012). This knowledge might also be
useful in the clinical context where an acute or chronic B cell
mediated inflammation is present, such as autoimmune diseases
or osteoarthritis.
MSCs are also well known to express major histocompatibility
complex (MHC) class I molecules on their surface, but to
have a minimal expression of MHC class II (Le Blanc et al.,
2003) and co-stimulatory molecules such as CD80 and CD86
(Chamberlain et al., 2007). Addition of IFN-γ has been reported
to enhance the expression of MHC class I and II (Majumdar
et al., 2003), but it does not seem to increase the levels of
CD80 and CD86 (Chinnadurai et al., 2014). Here, we show that
unprimed pMSCs express high levels of MHC class I (HLA-
ABC) and low levels of MHC class II (HLA-DR), CD80 and
CD86. However, IFN-γ stimulation upregulated the levels of
HLA-DR and both co-stimulatory molecules on pMSCs. This
increase could mean that pMSCs would be more prone to act as
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FIGURE 3 | IFN-γ primed pMSCs significantly reduce the proliferation rates on naïve, memory and total numbers of B cells compared to unprimed cells. Stimulated
(+anti-CD40, anti-IgM, and IL-2) B cells were co-cultured with either IFN-γ primed or unprimed pMSCs. B cells were retrieved and analyzed by flow cytometry after 7
days. (A) FACS gating strategy of viable CD19+ B cells that were classified according to the expression of CD27 into memory (CD27+), naïve (CD27−) B cells, or
plasmablasts (CD27high CD38high). (B) Relative proliferation of B cells when co-cultured with IFN-γ primed or unprimed pMSCs. Results are shown as the 1/MFI
(CFSE) of CD19+ viable cells (total B cells), CD27+ cells (memory), and CD27− cells (naïve) relative to the B cell stimulated condition. N = 3 B cell donors co-cultured
with 1 pMSC donor in duplicates or triplicates. Figures show means ± SD. *** p < 0.001.
FIGURE 4 | IFN-γ primed pMSCs but not unprimed significantly decrease plasmablast differentiation and IgG production. (A) Plasmablast frequencies were measured
upon 7 days of co-culture of stimulated B cells with IFN-γ primed or unprimed pMSCs. Results are expressed as the % of viable CD19+ CD27high CD38high cells. (B)
IgG concentration (ng/mL) was detected in the supernatants of stimulated B cells and IFN-γ primed or unprimed pMSCs by ELISA. N = 3 different B cell donors
co-cultured with 1 pMSC donor Results are shown as means ± SD. * p < 0.05; ** p < 0.01.
antigen presenting cells and activate T cells under inflammatory
conditions (Lim et al., 2012). Many studies have discussed the
crucial role of IFN- γ on MSCs immunomodulatory abilities
toward T cells (Krampera et al., 2006; Ryan et al., 2007). Since
an increased immunosuppressive effect from MSCs upon T cells
under inflammatory conditions has been linked to a higher IDO
activity (Meisel et al., 2004), we examined the gene expression
of IDO on pre-primed pMSCs. Our results showed that, in
contrast to previous studies (Ryan et al., 2007; Wobma et al.,
2018), IFN-γ priming did not affect pMSCs immunomodulatory
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abilities upon T cells. However, IFN-γ significantly upregulated
the gene expression of IDO in all pMSCs donors. Therefore,
it is possible that the upregulation of HLA-DR, CD80, and
CD86 triggered by IFN-γ on pMSCs counteracted the IDO
mediated enhancement on their immunomodulatory abilities
upon T cells. The extent of this upregulation was observed
to be donor dependent. This indicates that intrinsic variation
among pMSCs donors might impact the immunomodulatory
abilities of pMSCs toward T cells according to the degree of
expression of co-stimulatory molecules in an inverse manner.
Despite this, under inflammatory conditions, pMSCs were still
able to suppress T cell proliferation in a similar trend than
unprimed pMSCs. Previous studies have reported as well that
the immunomodulatory potency of MSCs is highly related to the
inflammatory milieu created by T cells (Kronsteiner et al., 2011).
Hence, the cytokine profile of T cells might in turn affect the
immunomodulatory effect of MSCs on immune cells.
Differences in the immunomodulatory abilities of IFN- γ
primed pMSCs compared to other sources of aMSCs may
depend on multifactorial pathways that have been described
to play a role in the degree of immunomodulation on MSCs
toward T and B cells. Luk et al. (2017) previously reported
that upon IFN-γ addition, MSCs inhibited B cell proliferation
as well as IgG production and regulatory B cells (Breg)
formation through the tryptophan depleting activity of the
enzyme IDO. Some studies have reported the involvement of
other immunomodulatory mechanisms, such as Galectin-9 (Gal-
9) which significantly reduced IgG titers in an in vivo murine
model (Ungerer et al., 2014). The Cyclooxygenase 2 (COX-2)
pathway has also been indicated to play a role in Breg suppression
through IL-10 depletion (Hermankova et al., 2016). Signaling
pathways involving the release of metalloproteinase-processed
CC-chemokine ligand 2 (CCL-2) by MSCs controlled by the
downregulation of olfactory 1/early B cell factor–associated zinc-
finger protein (OAZ) have been proposed as a mechanism of
MSC inhibition of IgG synthesis on B cells (Feng et al., 2014).
Moreover, it is also important to remark that different extents
in the increase of co-stimulatory molecules on pMSCs surface,
which seems to be donor-dependent as presented in this study,
might entail as well differences in IFN- γ primed pMSCs
immunomodulatory abilities. This is due to the fact that a
higher upregulation of these co-stimulatory molecules, such as
CD80 and CD86, in certain donors may negatively impact the
immunosuppressive potential of IFN- γ primed pMSCs. Hence,
this intrinsic donor variability on the immune profile of pMSCs
needs to be taken into account when considering using pMSCs
for immune therapies.
Together, we show that IFN-γ priming exerts an impact
on the expression of immune markers and co-stimulatory
molecules on a novel source of pediatric MSCs. In this context,
pMSCs maintain their immunomodulatory abilities upon T cells,
significantly suppress B cell proliferation, as well as plasmablast
differentiation and antibody production. In vivo, this might
mean that upon receiving certain inflammatory signals, such
as IFN-γ produced by activated T cells, pMSCs safeguard
their immunomodulatory status toward T cells, and gain anti-
proliferative abilities upon B cells, avoiding an allo-antibody
immune response. This knowledge is useful for the design of
novel immunotherapies in several types of diseases where a
chronic inflammation is present, as well as in the areas of
regenerative medicine and solid organ transplantation by using
a novel MSC source with enhanced differentiation abilities and
an immune privileged condition.
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